الفهرس 
I NTRO DUCTIONOnly 14 pages are availabe for public view
 |  | from | 127 |  |  |
| | | from | 127 | | |
Abstract
peositron emission tomography (PET)with18fluorine (18f) flurodeoxy glucose (FDG) has an important role in oncology. Its role in management of breast cancer is evolving recently. Imaging of metabolic pathways serves as an alternative way for visualizing the treatment effects; furthermore, metabolic reduction within the tumor precedes the anatomic response to therapy. PET with 18 F- FDG has been used to evaluate the clinical response to NAC in patient with breast cancer.
The 18F-FDG uptake, expressed semiquantitatively by standardized uptake value (SUV), that has been reported as a strong predictor of clinical and pathologic response. PET CT allows the assessment of metabolic changes in residual tumor cells rather than just morphological changes; which was very beneficial with non-mass forming tumors.
In our study we included 44 patients with different locally breast and metastatic breast lesions. All patients had a Pretreatment PET CT examination and post chemotherapy PET CT follow up examination. Finally, the results were compared to the histopathological results. It was found that assessment of NAC therapy response by PET CT had a sensitivity of 100 %, specificity of 76.5 % and accuracy of 90.9% using PERCIST1 system.
There was no significant difference between the pretreatment mean SUVmax value of the patients with different pathological subtypes. However, there was a significant difference between the SUVmax values of these subtypes after NAC.